Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-1)

October 1, 2026 updated by: GlaxoSmithKline

A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

981

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Argentina
      • Buenos Aires, Argentina, 1023
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Abel Esteban Bordon
      • Buenos Aires, Argentina, C1425AGC
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Manuela Garro
      • Buenos Aires, Argentina, C1425BEN
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Anahi Yanez
        • Contact:
        • Contact:
      • Buenos Aires, Argentina, C1121ABE
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Verónica Lawriwskyj
      • Buenos Aires, Argentina, 7600
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carlos De la Vega
      • Ciudad Autonoma de Bueno, Argentina, C1414AIF
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hernan Piza
      • Mendoza, Argentina, 5500
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Pablo Saez Scherbovsky
        • Contact:
        • Contact:
      • Mendoza, Argentina, M5500CCG
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pedro Carlos Elias
      • Paraná, Argentina, 3100
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Luis Larrateguy
      • Rosario, Argentina, S2002OJN
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Fernando Massola
      • San Juan Bautista, Argentina, 1888
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Andrea Medina
      • San Miguel de Tucumán, Argentina, T4000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hector Altieri
      • San Miguel de Tucumán, Argentina, T4000IFL
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Roxana Willigs Rolon
      • San Miguel de Tucumán, Argentina, 4000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mercedes Espeche
    • Provincia de Bs AS
      • La Plata, Provincia de Bs AS, Argentina, 1900
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • GABRIEL GARCIA
  • Belgium
      • Aalst, Belgium, 9300
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dimitri Stylemans
      • Genk, Belgium, 3600
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • David Ruttens
      • Kortrijk, Belgium, 8500
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mathias Leys
      • Liège, Belgium, 4000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Florence Schleich
        • Principal Investigator:
          • Geoffroy de Fooz
      • Namur, Belgium, 5101
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jean-Benoît MARTINOT
      • Sint-Niklaas, Belgium, 9100
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jonas Yserbyt
  • Canada
    • British Columbia
      • Richmond, British Columbia, Canada, V6V 2L1
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alexandra Lucas
    • Ontario
      • Ajax, Ontario, Canada, L1S 2J5
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • George Philteos
        • Contact:
        • Contact:
      • Toronto, Ontario, Canada, M5T 3A9
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Kenneth Chapman
        • Contact:
        • Contact:
      • Windsor, Ontario, Canada, N8X 1T3
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Syed Anees
        • Contact:
        • Contact:
    • Quebec
      • Saint-Charles-Borromée, Quebec, Canada, J6E 2B4
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Bonavuth Pek
        • Contact:
        • Contact:
      • Sherbrooke, Quebec, Canada, J1L 0H8
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Philippe Lachapelle
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7N 0W8
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Darcy Marciniuk
  • Chile
      • Curicó, Chile, 3341643
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Victor Martinez Hagen
  • China
      • Beijing, China, 100020
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yingxiang lin
        • Contact:
        • Contact:
      • Beijing, China, 100034
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • guangfa wang
        • Contact:
        • Contact:
      • Changchun, China, 130021
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Liping Peng
        • Contact:
        • Contact:
      • Changchun, China, 130041
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • wang ke
      • Changsha, China, 410013
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Lihua Xie
      • Chengdu, China, 610041
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • fuqiang Wen
      • Chongqing, China, 400038.
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Xiangdong Zhou
        • Contact:
        • Contact:
      • Dongguan, China, 523059
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Guodong Hu
      • Fuyang, China, 236000
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Bin Liu
        • Contact:
        • Contact:
      • Guangzhou, China, 510150
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Principal Investigator:
          • Liping Wei
        • Contact:
      • Guangzhou, China, 510180
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Zhuxiang Zhao
      • Guilin, China, 541002
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Bin Huang
      • Hangzhou, China, 310005
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sheng Huang
        • Contact:
        • Contact:
      • Hangzhou, China, 310000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Limin Wang
      • Hefei, China, 230001
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Xiaodong Mei
      • Hohhot, China, 010017
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Maoye Xu
      • Hohhot, China, 010050
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Xiuhua Fu
        • Contact:
        • Contact:
      • Huizhou, China, 516000
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Feng Wu
        • Contact:
        • Contact:
      • Huizhou, China, 516001
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • changqing lin
      • Jiangmen, China, 529000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mingjiang Lin
      • Jiangmen, China, 529030
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • yanming huang
        • Contact:
        • Contact:
      • Jiangsu, China, 221004
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Bi Chen
        • Contact:
        • Contact:
      • Jiangxi, China
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Limin Dong
      • Jinan, China, 250012
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yiqing Qu
        • Contact:
        • Contact:
      • Kunming, China
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yunhui Zhang
      • Kunming, China, 650032
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Zhuang Luo
      • Lianyungang, China, 222006
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Fukuan Zhong
      • Liuzhou, China, 545006
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Lin Chen
        • Contact:
        • Contact:
      • Meizhou, China, 514700
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • du yanjia
      • Mianyang, China
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Weiguo Xu
        • Contact:
        • Contact:
      • Nanchang, China, 330038
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Xiya Wu
      • Nanchang, China, 330000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Qing Yang
      • Qingdao, China, 266011
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • wei han
      • Qingyuan, China, 511500
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dongbo Tian
      • Qinhuangdao, China, 66000
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Hua Qiao
        • Contact:
        • Contact:
      • Shanghai, China, 200032
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yuanlin Song
        • Contact:
        • Contact:
      • Shanghai, China
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Xianghuai XU
      • Shanghai, China, 201199
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Xiwen Gao
      • Shanghai, China, 201299
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Wenchao Gu
      • Suzhou, China
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Wei Lei
      • Taiyuan, China, 300201
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yi Jiang
      • Taizhou, China, 317000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jiaxi Feng
      • Weifang, China
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Guoru Yang
      • Wenzhou, China, 325000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Liqin wu
      • Wuhan, China, 430014
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yi Hu
        • Contact:
        • Contact:
      • Wuxi, China, 214023
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Tao Bian
        • Contact:
        • Contact:
      • Xi'an, China, 710061
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Manxiang Li
      • Xiamen, China, 361004
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Huiqing Zeng
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yihua Lin
      • Yinchuan, China, 750001
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Lijun Chen
        • Contact:
        • Contact:
      • Zhanjiang, China, 524045
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Junxian Chen
      • Zhengzhou, China, 450052
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Aiguo Xu
      • Zigong, China, 643036
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Zhiping Deng
      • Ürümqi, China, 830054
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • wang zaiyi
    • Hainan
      • Haikou, Hainan, China, 570311
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Wu Haihong
    • Hunan
      • Changsha, Hunan, China, 410015
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yingqun Zhu
    • Sichuan
      • Chengdu, Sichuan, China, 611130
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Xiao Liu
  • Croatia
      • Split, Croatia, 21000
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Vide Popovic
        • Contact:
        • Contact:
      • Zagreb, Croatia, 10000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mirna Vergles
  • Denmark
      • Aalborg, Denmark, 9000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ulla Moller Weinreich
      • Hvidovre, Denmark, 2650
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Charlotte Ulrik
    • Region Sjælland
      • Roskilde, Region Sjælland, Denmark, 4000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Christian Meyer
  • France
      • Amiens, France, 80054
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Claire ANDREJAK
        • Contact:
        • Contact:
      • Blois, France, 41000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alexandre Bleinc
      • Caen, France, 14000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Aurelien Justet
      • La Tronche, France, 38700
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Bruno Degano
      • Lyon, France, 69004
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Gilles Devouassoux
      • Nice, France, 06001
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Valentin Stalder
      • Pessac, France, 33600
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pierre-Olivier GIRODET
      • Toulouse, France, 31059
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sandrine Pontier-Marchandise
      • Villeurbanne, France, 69100
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jean-Marc Dot
    • Aisne
      • Saint-Quentin, Aisne, France, 2100
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • DOUADI YOUCEF
    • Bouches-du-Rhône
      • Marseille, Bouches-du-Rhône, France, 13015
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marion Gouitaa
  • Germany
      • Ahrensburg, Germany, 22926
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sameer Kulkarni
      • Berlin, Germany, 12157
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Michael Sebert
        • Contact:
        • Contact:
      • Berlin, Germany, 14059
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Timo Weiss
      • Bonn, Germany, 53127
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Dirk Skowasch
        • Contact:
        • Contact:
      • Frankfurt am Main, Germany, 60389
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Claus Keller
        • Contact:
        • Contact:
      • Frankfurt am Main, Germany, 60596
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Marc Oliver Kornmann
        • Contact:
        • Contact:
      • Giessen, Germany
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Natascha Sommer
      • Kiel, Germany, 24105
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jan Heyckendorf
      • Mainz, Germany, 55128
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stephanie Korn
        • Contact:
        • Contact:
      • München, Germany, 81241
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Rainald Fischer
        • Contact:
        • Contact:
      • Wiesbaden, Germany, 65183
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Peter Fried
      • Wuppertal, Germany, 42283
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sven Stieglitz
      • Würzburg, Germany, 97074
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Stefan Baron
    • Baden-Wurttemberg
      • Löwenstein, Baden-Wurttemberg, Germany, 74245
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Biljana Joves
    • Bavaria
      • Donaustauf, Bavaria, Germany, 93093
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Maximilian Malfertheiner
    • Lower Saxony
      • Peine, Lower Saxony, Germany, 31224
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Christian Schlenska
        • Contact:
        • Contact:
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Germany, 45239
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sivagurunathan Sutharsan
  • Hungary
      • Budapest, Hungary, 1044
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alpar HORVATH
      • Budapest, Hungary, 1121
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ildikó Horváth
      • Pécs, Hungary, 7635
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Marta Papp
        • Contact:
        • Contact:
      • Törökbálint, Hungary, 2045
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Gabriella Gálffy
  • Ireland
      • Cork, Ireland, T12 DC4A
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Desmond Murphy
        • Contact:
        • Contact:
      • Drogheda, Ireland, A92 VW28
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Omar Omaima
      • Dublin, Ireland, D15 X40D
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Abirami Subramaniam
      • Galway, Ireland
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michael Harrison
      • Mullingar, Ireland, N91 NA43
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Junaid Khan
    • Co. Dublin
      • Dublin, Co. Dublin, Ireland, NR0A
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Patrick Mitchell
  • Japan
      • Chiba, Japan, 260-8677
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jun Ikari
      • Chiba, Japan, 279-0001
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yasuhiro Norisue
      • Chiba, Japan, 260-0852
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yasuo Takiguchi
      • Fukuoka, Japan, 805-8508
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kunihiro Suzuki
      • Fukuoka, Japan, 802-0052
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tetsuya Kawano
      • Fukuoka, Japan, 820-8505
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kazunori Tobino
      • Fukuoka, Japan, 812-0054
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Isamu Okamoto
        • Contact:
        • Contact:
      • Fukushima, Japan, 960-1295
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yoko Shibata
      • Gifu, Japan, 509-6134
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hiroyuki Ohbayashi
      • Hokkaido, Japan, 062-0931
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Satoshi Fuke
      • Hyōgo, Japan, 663-8501
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Takashi Kijima
      • Hyōgo, Japan, 672-8064
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yuji Nakatani
      • Hyōgo, Japan, 650-0047
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ryo Tachikawa
      • Hyōgo, Japan, 651-0053
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hiroki Kawabata
      • Hyōgo, Japan, 670-0849
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kunihiko Terada
      • Ibaraki, Japan, 300-0812
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Norihiro Kikuchi
      • Ishikawa, Japan, 920-8650
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Toshiyuki Kita
      • Kagawa, Japan, 762-0043
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hiroyuki Nakamura
      • Kanagawa, Japan, 232-0024
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • makoto kudo
      • Kanagawa, Japan, 221-0855
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kazuhito Miyazaki
      • Kanagawa, Japan, 229-1103
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jun Shinada
      • Kyoto, Japan, 610-0113
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kensuke Sumi
      • Mie, Japan, 515-8544
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Osamu Hataji
      • Mie, Japan, 510-8561
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Masamichi Yoshida
        • Contact:
        • Contact:
      • Nankoku-shi, Japan, 783-8509
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tsutomu Shinohara
      • Niigata, Japan, 940-0840
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Toshio Kiguchi
      • Niigata, Japan, 940-8621
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hideo Sato
      • Okayama, Japan, 701-1192
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Keiichi Fujiwara
      • Omuta Shi, Japan, 837-0911
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Satoru Fukuyama
      • Osaka, Japan, 543-8555
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Chie Yoshimura
      • Osaka, Japan, 560-8552
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Keisuke Miki
        • Contact:
        • Contact:
      • Osaka, Japan, 586-8521
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Miyuki Okuda
      • Shizuoka, Japan, 430-8525
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Mikio Toyoshima
        • Contact:
        • Contact:
      • Shizuoka, Japan, 420-0853
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Masato Fujii
      • Shizuoka, Japan, 432-8002
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jun Sato
      • Shizuoka, Japan, 426-0077
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Naoki Koshimizu
        • Contact:
        • Contact:
      • Shizuoka, Japan, 434-0015
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yutaro Nakamura
      • Tokyo, Japan, 103-0027
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Arihiro Kiyosue
      • Tokyo, Japan, 162-8655
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Manabu Suzuki
      • Tokyo, Japan, 113-8431
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kengo Koike
      • Tokyo, Japan, 105-8471
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Takanori Numata
      • Tokyo, Japan, 104-0031
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yasushi Fukushima
      • Tokyo, Japan, 140-8522
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Masaharu Shinkai
      • Tokyo, Japan, 204-8522
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hiroyuki Kokuto
      • Yamaguchi, Japan, 755-0067
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tsunahiko Hirano
      • Yokohama, Japan, 236-0004
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yu Hara
        • Contact:
        • Contact:
    • Fukuoka
      • Kitakyushu-shi, Fukuoka, Japan, 807-8555
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kazuhiro Yatera
  • Netherlands
      • Deventer, Netherlands, 7416 SE
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Margriet Stellingwerf
      • Enschede, Netherlands, 7512 KZ
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Wendy J.C. Moeskops-van Beurden
      • Harderwijk, Netherlands, 3844 DG
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Lisenka N. Boom
      • Hoofddorp, Netherlands, 2134 TM
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marijke Amelink
      • Nijmegen, Netherlands, 6532 SZ
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Rob Janssen
    • Gelderland
      • Zutphen, Gelderland, Netherlands, 7207 AE
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Martijn Goosens
        • Contact:
        • Contact:
    • North Brabant
      • Breda, North Brabant, Netherlands, 4818 CK
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Simone van der Sar
        • Contact:
        • Contact:
    • Overijssel
      • Zwolle, Overijssel, Netherlands, 8025 AB
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jan Willem K. van den Berg
  • Norway
    • Akershus
      • Lørenskog, Akershus, Norway, 1474
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gunnar Einvik
        • Contact:
        • Contact:
  • Poland
      • Bialystok, Poland, 15-044
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Robert Mroz
      • Bydgoszcz, Poland, 85-796
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jacek Dulęba
      • Krakow, Poland, 30-033
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Grażyna Pulka
      • Poznan, Poland, 60-693
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michał Springer
      • Rzeszów, Poland, 35-051
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Małgorzata Pawlukiewicz
      • Rzeszów, Poland, 35-205
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Slawomir Tokarski
      • Wroclaw, Poland, 54-153
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ewa Pisarczyk-Bogacka
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Poland, 61-578
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Danuta Madra-Rogacka
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Poland, 40-954
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Krzysztof Filipek
  • Portugal
      • Guarda, Portugal, 6300-749
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • José Silva
      • Lisbon, Portugal, 1649-035
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Paula Pinto
      • Lisbon, Portugal, 1500-458
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Susana Moreira
      • Lisbon, Portugal, 1500-650
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mónica Grafino
      • Setúbal, Portugal, 2900-722
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marta Fradinho
      • Vila Nova de Gaia, Portugal, 4400-346
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nuno Cortesao
    • Lisbon District
      • Loures, Lisbon District, Portugal, 2674-514
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Teresa Martin
    • Porto District
      • Senhora da Hora, Porto District, Portugal, 4464-513
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Daniel Reis
    • Setúbal District
      • Almada, Setúbal District, Portugal, 2805-267
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carlos Couto
  • Slovakia
      • Košice, Slovakia, 040 01
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Martin Orolin
      • Spišská Nová Ves, Slovakia, 052 01
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Slavomir Hrebenar
  • Spain
      • Alzira, Spain, 46600
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Elsa Naval Sendra
        • Contact:
        • Contact:
      • Barcelona, Spain, 8035
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Miriam Barrecheguren Fernández
        • Contact:
        • Contact:
      • Benalmádena, Spain, 29639
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Gustavo De Luiz Martinez
      • Ferrol, Spain, 15405
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carlota Rodríguez
      • GaldakaoVizcaya, Spain, 48960
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Amaia Aramburu Ojembarrena
      • Madrid, Spain, 28040
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carolina María Gotera Rivera
      • Madrid, Spain, 28050
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Walther Ivan Giron Matute
      • Marbella, Spain, 29603
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • María del Carmen Morillo Domínguez
      • Málaga, Spain, 29010
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Esperanza Doña Díaz
        • Principal Investigator:
          • José Luis Velasco Garrido
      • Palma de Mallorca, Spain, 070120
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Francisco de Borja García-Cosio Piqueras
      • Santander, Spain, 39008
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carlos Amado Diago
      • Seville, Spain, 41009
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Agustín Salvador Valido Morales
      • Zaragoza, Spain, 50009
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marta Marin Oto
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spain, 28223
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jose Maria Echave-Sustaeta
    • Málaga
      • Marbella, Málaga, Spain, 29603
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jose Maria Ignacio
  • Sweden
      • Lund, Sweden, SE-222 22
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Anders Luts
      • Stockholm, Sweden, 11727
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • AKE OLSSON
      • Stockholm, Sweden, SE-113 29
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Peter Bosson
  • Switzerland
      • Aarau, Switzerland, 5001
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hans-Joachim Kabitz
      • Zurich, Switzerland, 8636
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marc Spielmanns
  • Taiwan
      • Changhua, Taiwan, 50006
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ching-Hsiung Lin
      • Kaohsiung City, Taiwan, 80756
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Chau-Chyun Sheu
      • Taichung, Taiwan, 407219
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ming-Cheng Chan
      • Taichung, Taiwan, 433
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ming-Lin Ho
      • Taipei, Taiwan, 11031
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pai-Chien Chou
      • Taipei, Taiwan, 11490
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Chen-Liang Tsai
      • Taipei, Taiwan, 220
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Shih-Lung Cheng
        • Contact:
        • Contact:
  • Turkey (Türkiye)
      • Çanakkale, Turkey (Türkiye), 17020
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pinar Mutlu
      • İzmit, Turkey (Türkiye), 41380
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • İlknur Başyiğit
    • Balcova
      • Izmir, Balcova, Turkey (Türkiye), 35340
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Aylin Alpaydin
    • Konyaaltı
      • Antalya, Konyaaltı, Turkey (Türkiye), 7070
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Aykut Cilli
    • Pamukkale
      • Denizli, Pamukkale, Turkey (Türkiye), 20070
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nese Dursunoglu
  • United States
    • California
      • Bakersfield, California, United States, 93301
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Tonny Tanus
        • Contact:
        • Contact:
      • Modesto, California, United States, 95355-4046
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jose Rodriguez
      • Newport Beach, California, United States, 92663
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ryan Klein
    • Delaware
      • Wilmington, Delaware, United States, 19803
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carole Guy
    • Florida
      • Bradenton, Florida, United States, 34209
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Patrick Weston
      • Brandon, Florida, United States, 33511-5706
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Principal Investigator:
          • Rafael Martinez
        • Contact:
      • Hialeah, Florida, United States, 33012
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Alberto Manzor
        • Contact:
        • Contact:
      • Hialeah, Florida, United States, 33016
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Juan Fernandez
      • Loxahatchee Groves, Florida, United States, 33470
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Neal Warshoff
        • Contact:
        • Contact:
      • Miami, Florida, United States, 33126
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Anish Dhadwal
        • Contact:
        • Contact:
      • Miami, Florida, United States, 33155
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Guillermo Somodevilla
        • Contact:
        • Contact:
      • Miami Lakes, Florida, United States, 33016
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Maria Elena Ocasio
      • Orange City, Florida, United States, 32763
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kristyna Paradis
      • Palm Springs, Florida, United States, 33406
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Luis Castillo Hernandez
        • Contact:
        • Contact:
      • Palmetto Bay, Florida, United States, 33176-7296
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michael Feldman
      • Pensacola, Florida, United States, 32503-2698
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Peter Bercz
      • Tamarac, Florida, United States, 33321
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Neena Chandrasekaran
      • Tampa, Florida, United States, 33614
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • GERMAN ALVAREZ
      • The Villages, Florida, United States, 32162
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Angela Okolie
    • Georgia
      • Riverdale, Georgia, United States, 30274
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Deon Miller
        • Contact:
        • Contact:
      • Stonecrest, Georgia, United States, 30038
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Rabahuddin Syed
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Daniel Meza
    • Maryland
      • Baltimore, Maryland, United States, 21224
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sarath Raju
    • Michigan
      • Clarkston, Michigan, United States, 48346
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dean Moscovic
      • Flint, Michigan, United States, 48504-4730
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ahmed Arif
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kaharu Sumino
    • Nevada
      • Henderson, Nevada, United States, 89052-5015
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Vikas Sayal
      • Las Vegas, Nevada, United States, 89123-2874
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Vrijendra Hoon
        • Contact:
        • Contact:
      • Reno, Nevada, United States, 89502
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Farah Madhani-Lovely
    • New York
      • North Massapequa, New York, United States, 11758
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michael DiGiovanna
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Farhan Ahmed
      • Winston-Salem, North Carolina, United States, 27104
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jessica Bon
    • South Carolina
      • Greenville, South Carolina, United States, 29607
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Eric Garcia-Torres
      • Rock Hill, South Carolina, United States, 29732
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Michael Denenberg
        • Contact:
        • Contact:
    • Tennessee
      • Franklin, Tennessee, United States, 37067
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Aaron Milstone
        • Contact:
        • Contact:
    • Texas
      • Corsicana, Texas, United States, 75110
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • John Updegrove
      • Dallas, Texas, United States, 75234
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Chaitanya Tatineni
      • Houston, Texas, United States, 77084
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ajay Jain
      • Houston, Texas, United States, 77089
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sandeep Gupta
      • Houston, Texas, United States, 77058-2805
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alfred Maksoud
      • McKinney, Texas, United States, 75069
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Shahrukh Kureishy
      • Pearland, Texas, United States, 77584
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mohammad Siddiqui

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants must be greater than or equal to (>=) 40 to less than or equal to (<=) 80 years of age, at the time of signing the informed consent

  • Elevated blood eosinophil count (BEC).

  • Moderate to severe COPD with frequent exacerbations, defined as:

    • A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year
    • A post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio of less than (<) 0.70 and a post- bronchodilator FEV1 >30 percent (%) and <= 80% predicted normal values
    • A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening

  • COPD assessment test (CAT) score >=10 at Visit 1

  • Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years.

  • Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1

  • Body mass index (BMI) >=16 kilogram per square meter (kg/m^2).

  • Male or eligible female participants

Exclusion Criteria:

The following subjects are excluded:

  • Participants with a current or prior physician diagnosis of asthma
  • Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease
  • Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1
  • Lung resection: Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure
  • Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1.
  • Continuous oxygen: Participants requiring oxygen supplementation for more than 16 hours per day to maintain resting oxygen saturation greater than 88%
  • Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension
  • Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure [BiPAP] or Continuous Positive Airway Pressure [CPAP])
  • Unstable cardiovascular disease or arrhythmia.
  • Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Depemokimab

Participants will be administered depemokimab along with standard of care (SoC).
Biological: Depemokimab

Depemokimab as a sterile liquid formulation will be administered.

Other Names:
  • GSK3511294
Placebo Comparator: Placebo

Participants will be administered placebo along with SoC.
Drug: Placebo

Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Annualized Rate of Moderate/Severe Exacerbations
Time Frame: From Baseline up to Week 104

Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (i.e., greater than or equal to [>=] 24 hours) or result in death. The frequency of moderate/ severe exacerbations expressed as an annualized exacerbation rate will be evaluated.
From Baseline up to Week 104

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to First Moderate/Severe Exacerbation
Time Frame: From Baseline up to Week 104

Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (i.e., greater than or equal to [>=] 24 hours) or result in death.
From Baseline up to Week 104
Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score at Week 52
Time Frame: From Baseline up to Week 52

The SGRQ total score will be measured using the SGRQ for COPD [SGRQ-C]. The SGRQ-C is a 40-item participant questionnaire designed to measure health impairment by addressing the frequency of respiratory symptoms (questions 1-7) and the participant's current state (questions 8-14). The questions are designed to be self-completed by the participant. The total score will be calculated on 0-100 rating scale and scores expressed as a percentage of overall impairment. Higher scores indicate greater impairment of health.
From Baseline up to Week 52
Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total Score at Week 52
Time Frame: From Baseline up to Week 52

E-RS: COPD consists of 11 items from the 14-item Exacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcomes (EXACT) instrument. E-RS: COPD is intended to capture information related to the respiratory symptoms of COPD, i.e., breathlessness, cough, sputum production, chest congestion, and chest tightness. The ERS: COPD has a scoring range of 0 to 40, higher scores indicate more severe symptoms.
From Baseline up to Week 52
Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization
Time Frame: From Baseline up to Week 104

Annualized rate of exacerbations requiring ED Visit or Hospitalization (For pooled analysis across studies 222714 and 222725) will be assessed.
From Baseline up to Week 104
Annualized Rate of Severe Exacerbations
Time Frame: From Baseline up to Week 104

Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (i.e., greater than or equal to [>=] 24 hours) or result in death. Annualized rate of severe exacerbations (For pooled analysis across studies 222714 and 222725) will be assessed.
From Baseline up to Week 104

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Investigators

  • Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2025

Primary Completion (Estimated)

December 13, 2028

Study Completion (Estimated)

February 14, 2029

Study Registration Dates

First Submitted

April 28, 2025

First Submitted That Met QC Criteria

April 28, 2025

First Posted (Actual)

May 6, 2025

Study Record Updates

Last Update Posted (Actual)

October 5, 2026

Last Update Submitted That Met QC Criteria

October 1, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 222714
  • 2024-520418-22 (Other Identifier: EU CT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD Sharing Time Frame

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD Sharing Access Criteria

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe